Robert W. Baird Issues Pessimistic Forecast for Vor Biopharma (NYSE:VOR) Stock Price

Vor Biopharma (NYSE:VOR) had its price target dropped by equities researchers at Robert W. Baird from $22.00 to $14.00 in a research note issued to investors on Friday,Benzinga reports. The firm presently has an “outperform” rating on the stock.

Several other brokerages have also recently issued reports on VOR. HC Wainwright restated a “buy” rating and issued a $17.50 price target on shares of Vor Biopharma in a research report on Friday, September 6th. JMP Securities restated a “market outperform” rating and set a $12.00 price target on shares of Vor Biopharma in a research note on Friday, September 6th. Finally, Barclays lowered their price objective on shares of Vor Biopharma from $10.00 to $3.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 14th. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Vor Biopharma currently has an average rating of “Buy” and an average price target of $11.36.

Vor Biopharma Price Performance

Shares of Vor Biopharma stock opened at $0.96 on Friday. The firm’s fifty day simple moving average is $0.80 and its 200-day simple moving average is $1.07. Vor Biopharma has a 12 month low of $0.63 and a 12 month high of $3.14. The stock has a market capitalization of $65.53 million, a price-to-earnings ratio of -0.55 and a beta of -0.40.

Vor Biopharma (NYSE:VOR) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.41) EPS for the quarter, meeting analysts’ consensus estimates of ($0.41). Analysts anticipate that Vor Biopharma will post -1.51 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Hsbc Holdings PLC boosted its position in shares of Vor Biopharma by 177.0% during the 2nd quarter. Hsbc Holdings PLC now owns 49,038 shares of the company’s stock worth $51,000 after purchasing an additional 31,333 shares in the last quarter. Cubist Systematic Strategies LLC purchased a new position in shares of Vor Biopharma in the 2nd quarter valued at about $53,000. Acadian Asset Management LLC acquired a new stake in shares of Vor Biopharma in the first quarter valued at about $126,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Vor Biopharma during the second quarter worth about $63,000. Finally, Rosalind Advisors Inc. purchased a new position in Vor Biopharma in the third quarter valued at about $54,000. Institutional investors and hedge funds own 97.29% of the company’s stock.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.